Contrasting CytomX Therapeutics (CTMX) and Its Rivals

CytomX Therapeutics (NASDAQ:CTMX) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare CytomX Therapeutics to related businesses based on the strength of its profitability, valuation, analyst recommendations, earnings, risk, dividends and institutional ownership.

Profitability

This table compares CytomX Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-608.98%	-33.97%	-27.19%
CytomX Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Analyst Recommendations

This is a summary of current recommendations for CytomX Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1	1	9	1	2.83
CytomX Therapeutics Competitors	9873	15287	45633	1598	2.54

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 493.14%. As a group, “Biotechnology” companies have a potential upside of 125.12%. Given CytomX Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than its rivals.

Volatility & Risk

CytomX Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, CytomX Therapeutics’ rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Insider & Institutional Ownership

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CytomX Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CytomX Therapeutics	$76.20 million	-$17.37 million	-4.08
CytomX Therapeutics Competitors	$702.30 million	$9.48 million	-18.96

CytomX Therapeutics’ rivals have higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

CytomX Therapeutics beats its rivals on 9 of the 12 factors compared.

CytomX Therapeutics Company Profile

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies.